Analysts Set Expectations for AURA FY2028 Earnings

Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) - Research analysts at HC Wainwright issued their FY2028 earnings estimates for shares of Aura Biosciences in a research report issued on Wednesday, May 28th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings of ($1.60) per share for the year. HC Wainwright currently has a "Buy" rating and a $22.00 target price on the stock. The consensus estimate for Aura Biosciences' current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Aura Biosciences' FY2029 earnings at ($1.17) EPS.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.08).

Several other brokerages also recently weighed in on AURA. Citigroup reiterated an "outperform" rating on shares of Aura Biosciences in a research report on Wednesday, March 26th. JMP Securities restated a "market outperform" rating and set a $19.00 price objective on shares of Aura Biosciences in a research note on Friday, May 23rd. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and an average price target of $22.00.

Aura Biosciences Trading Up 2.6%

NASDAQ AURA traded up $0.15 during trading hours on Thursday, reaching $6.01. The company's stock had a trading volume of 71,674 shares, compared to its average volume of 206,518. The business has a 50-day simple moving average of $5.63 and a 200 day simple moving average of $7.20. Aura Biosciences has a 52 week low of $4.35 and a 52 week high of $12.38. The stock has a market cap of $302.12 million, a PE ratio of -3.47 and a beta of 0.43.

Insider Buying and Selling at Aura Biosciences

In related news, insider Conor Kilroy sold 7,162 shares of the firm's stock in a transaction that occurred on Wednesday, April 16th. The shares were sold at an average price of $5.49, for a total transaction of $39,319.38. Following the completion of the sale, the insider now directly owns 179,313 shares in the company, valued at approximately $984,428.37. This trade represents a 3.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Anthony S. Gibney purchased 50,000 shares of the firm's stock in a transaction on Friday, May 16th. The stock was acquired at an average price of $4.90 per share, for a total transaction of $245,000.00. Following the transaction, the insider now owns 58,452 shares of the company's stock, valued at $286,414.80. The trade was a 591.58% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders sold 9,578 shares of company stock valued at $52,067. 5.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Aura Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Long Focus Capital Management LLC grew its holdings in shares of Aura Biosciences by 123.9% in the 4th quarter. Long Focus Capital Management LLC now owns 2,537,774 shares of the company's stock worth $20,861,000 after acquiring an additional 1,404,228 shares during the last quarter. Levin Capital Strategies L.P. boosted its position in shares of Aura Biosciences by 169.1% in the 4th quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company's stock valued at $10,255,000 after purchasing an additional 783,984 shares during the period. Acorn Capital Advisors LLC purchased a new position in Aura Biosciences in the 1st quarter worth about $3,460,000. B Group Inc. acquired a new stake in Aura Biosciences during the 4th quarter worth about $3,885,000. Finally, Regency Capital Management Inc. DE raised its holdings in Aura Biosciences by 23.0% during the 1st quarter. Regency Capital Management Inc. DE now owns 749,482 shares of the company's stock worth $4,392,000 after buying an additional 140,058 shares during the period. Institutional investors and hedge funds own 96.75% of the company's stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.